The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon

Frič, Pavol; Zavoral, Miroslav

doi:10.1097/00042737-200303000-00015

Cited by 102 publications

(65 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…S1 in the supplemental material). In vivo approaches using the controlled biofilm capacities of innocuous bacteria could thus be envisaged (i) to challenge deleterious biofilms found in both industrial and medical settings through bacterial interference or competitive adhesion to the surface (77) or through the production of toxic or matrix-dissolving compounds such as cellulase and dispersins, (ii) to optimize the persistence of probiotic strains (15,19,24,27,28,31,33,37,64), and (iii) to improve-via stronger heterologous bacterial interactions-the establishment, in nonsterile soil microcosms or in mixed bioreactors, of strains with desirable or genetically engineered features and their development as biosensors or agents in bioremediation processes (8,22,26,53,65,72).…”

Section: Discussionmentioning

confidence: 99%

Tight Modulation of Escherichia coli Bacterial Biofilm Formation through Controlled Expression of Adhesion Factors

Quéré

Ghigo

et al. 2007

Appl Environ Microbiol

View full text Add to dashboard Cite

Despite the economic and sanitary problems caused by harmful biofilms, biofilms are nonetheless used empirically in industrial environmental and bioremediation processes and may be of potential use in medical settings for interfering with pathogen development. Escherichia coli is one of the bacteria with which biofilm formation has been studied in great detail, and it is especially appreciated for biotechnology applications because of its genetic amenability. Here we describe the development of two new genetic tools enabling the constitutive and inducible expression of any gene or operon of interest at its native locus. In addition to providing valuable tools for complementation and overexpression experiments, these two compact genetic cassettes were used to modulate the biofilm formation capacities of E. coli by taking control of two biofilmpromoting factors, autotransported antigen 43 adhesin and the bscABZC cellulose operon. The modulation of the biofilm formation capacities of E. coli or those of other bacteria capable of being genetically manipulated may be of use both for reducing and for improving the impact of biofilms in a number of industrial and medical applications.Most natural and artificial surfaces available in the environment are prone to bacterial colonization. Following the initial adhesion event, cell-to-cell adhesion and the secretion of an extracellular matrix rapidly lead to the formation of a surfaceattached multicellular structure known as a biofilm (3,43,75,84). Besides being resistant to environmental shear forces, biofilm communities are also phenotypically more resistant to antibiotic and biocide treatments, a trait that poses important sanitary and economic problems. Indeed, biofilms formed by bacterial pathogens on medically relevant surfaces are difficult to eradicate and are thus often involved in the development of infections (12,13,48). Moreover, industrial biofouling resulting from bacterial biofilm formation is a major cause of pipe biocorrosion and reduces the efficiency of pharmaceutical or food bioprocesses (2,10,70,71).While recent studies have focused mainly on the negative impact of biofilms, bacterial biofilms can also have valuable applications, including those involving bioremediation and wastewater treatment bioreactor processes and the improvement of biomineralization or plant-bacteria symbiosis (1,14,40,42,52,62,73,74,80). Beneficial biofilms may also have medical applications, and the use of protective innocuous bacterial biofilms that interfere with the development of bacterial pathogens is considered a promising approach (19).Escherichia coli is a gram-negative enterobacterium that has been used extensively as a model to study biofilm development due to its relevance to the human biotic environment and its genetic amenability. In E. coli, various cell surface appendages were shown to be necessary to achieve mature biofilm development (78). Flagella, type I fimbriae, and curli are implicated in early adhesion steps, while the production of a polysaccharide-rich m...

show abstract

Section: Discussionmentioning

confidence: 99%

Tight Modulation of Escherichia coli Bacterial Biofilm Formation through Controlled Expression of Adhesion Factors

Quéré

Ghigo

et al. 2007

Appl Environ Microbiol

View full text Add to dashboard Cite

show abstract

“…This probiotic drug, Mutaflor ® , is successfully used in several countries for the treatment of various diseases of the digestive tract, including acute and prolonged diarrhea (Henker et al, 2007;, uncomplicated diverticular disease (Fric and Zavoral, 2003), and inflammatory bowel disease (IBD) (Kruis et al 1997, Matthes et al, 2010, Rembacken et al, 1999. It is particularly used for maintenance therapy of remission in patients with ulcerative colitis (UC) (Schultz, 2008).…”

Section: Fitness Factors Of Ecnmentioning

confidence: 99%

Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins

Seo¹,

Weibel

Wehkamp

et al. 2012

International Journal of Medical Microbiology

View full text Add to dashboard Cite

“…Its symptomatology includes pain in the hypogastrium, irregular bowel movements, abdominal bloating, and excessive flatulence. E. coli Nissle 1917 significantly prolongs remission after relapse treated with an intestinal antimicrobial and absorbent [151]. The effect is probably due to the stabilization of intestinal MF, normalization of intestinal dysfunction, and downregulation of hypersensitivity reactions.…”

Section: Diverticular Disease Of the Colonmentioning

confidence: 99%

Probiotics and prebiotics — renaissance of a therapeutic principle

Frič

2007

Open Medicine

View full text Add to dashboard Cite

AbstractProbiotics are nonpathogenic microorganisms mostly of human origin which, when administered in adequate amounts, confer a health benefit on the host and enable to prevent or improve some diseases. Probiotics may be a natural temporary constituent of the resident intestinal microflora, but their concentration is not sufficient for therapeutic purposes. The microbiota, the intestinal epithelium, and the mucosal immune system constitute the gastrointestinal ecosystem. All three components are essential for complete functional and developmental maturity of the system. The viability of intestinal microflora (including probiotic strains) requires the availability of nutritional substrates (prebiotics), i.e. various types of fiber and oligosaccharides. Prebiotics are cleaved by microbial enzymes to numerous substances (short-chain fatty acids, aminoacids, polyamines, growth factors, vitamins and antioxidants) indispensable for metabolic and functional activities of the intestinal mucosa. The principal probiotics in use include lactobacilli, bifidobacteria, some nonpathogenic strains of Escherichia coli, and Saccharomyces boulardii. These microbiota display favourable effects which qualify them for therapeutic use. For this purpose, probiotics have to fulfill a series of requirements verifying their efficacy and safety. Experimental and clinical studies examine the prerequisites for the administration of probiotics in digestive diseases, allergic and atopic affections, as well as in some extraintestinal conditions. Future goals of probiotic application include genomic analysis, controlled postnatal colonisation of the digestive tract, the use of probiotics as carriers of peroral vaccines, and recombinant probiotics with in-situ production and targeted application of therapeutic molecules.

show abstract

The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon

Abstract: Non-pathogenic strain Nissle significantly prolonged the remission period and improved the abdominal syndrome in symptomatic uncomplicated diverticular disease. A randomized, placebo-controlled study is recommended.

Cited by 102 publications

References 13 publications

Tight Modulation of Escherichia coli Bacterial Biofilm Formation through Controlled Expression of Adhesion Factors

Tight Modulation of Escherichia coli Bacterial Biofilm Formation through Controlled Expression of Adhesion Factors

Construction of recombinant E. coli Nissle 1917 (EcN) strains for the expression and secretion of defensins

Probiotics and prebiotics — renaissance of a therapeutic principle

Contact Info

Product

Resources

About